Monitor upcoming quarters for signs of revenue stabilization and commercialization progress in India; the significant impairment and cash burn raise sustainability concerns despite strategic advancements.
Price Chart
Executive Summary
Co-Diagnostics reported a significant year-over-year revenue decline from $3.9M to $0.6M in 2025, driven by lower grant revenue, while net loss widened to $46.9M due to an $18.9M non-cash impairment charge. Despite progress in joint ventures and regulatory milestones, the deteriorating financial performance dominates the narrative.
Key Financial Metrics
Key Facts
- Revenue dropped 84.7% YoY to $622,489 in 2025 from $3.92M in 2024, primarily due to lower grant revenue
- Net loss increased to $46.9M ($35.25/share) from $37.6M ($37.22/share) in 2024, driven by $18.9M impairment charge
- Cash, cash equivalents, and marketable securities fell to $11.9M from $29.7M in 2024
- Company raised $10.8M through two equity offerings in 2025, indicating dilutive capital raising
- Received CDSCO license for PCR Pro® instrument in India and expanded CoSara's territory across South Asia
Financial Impact
Revenue down 84.7% YoY, net loss up 24.7%, with $18.9M impairment charge and $18M cash burn
Risk Factors
- Continued reliance on dilutive equity financing to fund operations
- Failure to commercialize joint ventures (CoSara, CoMira) could further pressure financials
- Risk of Nasdaq delisting if bid price falls below $1.00 for 30 consecutive days during monitoring period
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-014129 |
| Document: form8-k.htm | 0001493152-26-014129 |
| Document: 0001493152-26-014129-index-headers.html | 0001493152-26-014129 |
| Document: 0001493152-26-014129-index.html | 0001493152-26-014129 |
| Document: 0001493152-26-014129.txt | 0001493152-26-014129 |
| 8-K Data (Synthetic) | 0001493152-26-014129 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | DEF 14A | $0.5473 | awaiting T+20 | — | $0.5470 (+0.05%) |
Oct 15, 2026 12d ago | 8-K/A | $0.7151 | awaiting T+20 | — | $0.5470 (+23.51%) |
Oct 13, 2026 14d ago | 8-K | $1.07 | awaiting T+20 | — | $0.5470 (+48.64%) |
Sep 16, 2026 5w ago | 8-K | $0.9408 $1.07 | ▲ +13.20% | ▲ +10.02% | $0.5470 (−41.86%) |
Sep 16, 2026 5w ago | 8-K | $0.9408 $1.07 | ▲ +13.20% | ▲ +10.02% | $0.5470 (−41.86%) |
Sep 4, 2026 7w ago | DEFA14A | $1.16 $1.10 | ▼ −5.17% | ▼ −5.77% | $0.5470 (−52.84%) |
Sep 2, 2026 7w ago | EFFECT | $1.16 $1.07 | ▲ +7.76% | ▲ +7.68% | $0.5470 (+52.84%) |
Jul 31, 2026 12w ago | 8-K | $1.44 $1.21 | ▲ +15.97% | ▲ +18.96% | $0.5470 (+62.01%) |
Jul 27, 2026 13w ago | 424B5 | $1.41 $1.23 | ▲ +12.77% | ▲ +16.15% | $0.5470 (+61.21%) |
Jun 1, 2026 21w ago | EFFECT | $6.20 $3.10 | ▲ +50.00% | ▲ +48.70% | $0.5470 (+91.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers